Journal: Inflammation

Article Title: GPR40 Attenuates Age-Related Macular Degeneration by Suppressing Retinal Microglial NLRP3 Inflammasome Activation Via ERK Signaling

doi: 10.1007/s10753-025-02380-8

Figure Lengend Snippet: GPR40 regulates microglia-induced inflammatory responses through the ERK signaling pathway. ( A ) Western blot analysis of p-ERK and t-ERK protein expression in mouse retinas from different groups. ( B – C ) Quantification of p-ERK and t-ERK protein expression in mouse retinas. ( D ) Western blot analysis of p-ERK and t-ERK protein expression in BV2 microglial cells from different groups. ( E – F ) Quantification of p-ERK and t-ERK protein expression in BV2 cells. ( G ) CCK-8 assay assessing the effects of different concentrations of C-C6 on BV2 cell viability.(H) Western blot analysis of p-ERK and t-ERK expression in BV2 microglial cells from different treatment groups. ( I – J ) Quantification of p-ERK and t-ERK expression in BV2 microglial cells from different treatment groups. ( K – M ) qPCR analysis of inflammatory cytokine expression in BV2 microglial cells from different treatment groups. Data are presented as mean ± SEM from at least three independent experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc multiple comparisons test. * P < 0.05, ** P < 0.01, * P < 0.001 vs. control or C-C6 agonist group; ^ P < 0.05, ^^ P < 0.01, ^^^ P < 0.001 vs. LPS or GW9508 agonist group

Article Snippet: The ERK agonist ceramide C6 (C-C6; sc-3527) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Western Blot, Expressing, CCK-8 Assay, Control

Journal: Inflammation

Article Title: GPR40 Attenuates Age-Related Macular Degeneration by Suppressing Retinal Microglial NLRP3 Inflammasome Activation Via ERK Signaling

doi: 10.1007/s10753-025-02380-8

Figure Lengend Snippet: GPR40 regulates microglia-induced inflammatory responses through the ERK signaling pathway. ( A ) Western blot analysis of p-ERK and t-ERK protein expression in mouse retinas from different groups. ( B – C ) Quantification of p-ERK and t-ERK protein expression in mouse retinas. ( D ) Western blot analysis of p-ERK and t-ERK protein expression in BV2 microglial cells from different groups. ( E – F ) Quantification of p-ERK and t-ERK protein expression in BV2 cells. ( G ) CCK-8 assay assessing the effects of different concentrations of C-C6 on BV2 cell viability. ( H ) Western blot analysis of p-ERK and t-ERK expression in BV2 microglial cells from different treatment groups. ( I – J ) Quantification of p-ERK and t-ERK expression in BV2 microglial cells from different treatment groups.(K–M) qPCR analysis of inflammatory cytokine expression in BV2 microglial cells from different treatment groups.Data are presented as mean ± SEM from at least three independent experiments. Statistical analysis was performed using one-way ANOVA followed by Tukey’s post hoc multiple comparisons test. *P < 0.05, **P < 0.01, *P < 0.001 vs. control or C-C6 agonist group; ^P < 0.05, ^^P < 0.01,^^^P < 0.001 vs. LPS or GW9508 agonist group

Article Snippet: The ERK agonist ceramide C6 (C-C6; sc-3527) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Western Blot, Expressing, CCK-8 Assay, Control